GENI.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 16:46):

Stats
Dzisiejszy wolumen	118 284
Średni wolumen	366 983
Kapitalizacja rynkowa	12.48M
EPS	£0 ( 2023-09-20 )
Następna data zysków	( £0 ) 2024-06-04
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.170
ATR14	£0.208 (2.95%)

GENinCode plc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GENinCode plc Finanse

Annual	2022
Przychody:	£1.43M
Zysk brutto:	£632 000 (44.20 %)
EPS:	£-0.0580

FY	2022
Przychody:	£1.43M
Zysk brutto:	£632 000 (44.20 %)
EPS:	£-0.0580

FY	2021
Przychody:	£1.15M
Zysk brutto:	£593 000 (51.39 %)
EPS:	£-0.0432

FY	2020
Przychody:	£960 801
Zysk brutto:	£523 016 (54.44 %)
EPS:	£-0.0111

Financial Reports:

No articles found.

GENinCode plc

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.